Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Diageo plc (DEO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Diageo plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Diageo plc trades at $81.81 (market cap $44.73B). The key difference: Alnylam Pharmaceuticals, Inc. and Diageo plc are close in size by market cap, and Diageo plc pays a 4.05% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DEO | |
|---|---|---|
Market Cap | $39.89B | $44.73B |
Sector | Health | Technology |
52-Week High | $491.22 | $115.33 |
52-Week Low | $278.09 | $72.47 |
Enterprise Value | $38.15B | $65.55B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Diageo (DEO) trades at $82.03, up 1.76% with bearish technical signals but mixed fundamentals. The stock shows strong profitability with 12.19% net margins and 22.29% ROE, though recent earnings were mixed with a Q2 2025 miss. Analyst sentiment leans positive with 49% buy ratings, but technical indicators show 15 sell signals versus 1 buy. Recent news highlights CEO Dave Lewis's upcoming strategy update amid US market challenges and promotional increases to stabilize sales.
The outlook remains cautious due to weak US demand and competitive pressures, but valuation at multi-year lows and cost-saving initiatives offer potential upside. Key risks include execution on the new strategy and consumer spending trends. Investors should weigh the dividend yield and recovery potential against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
